Loading...
•
Jun 30, 2020
Generation Bio Q2 2020 Earnings Report
Announced second quarter financial results and business updates.
Key Takeaways
Generation Bio reported a net loss of $17.7 million for the second quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $301.1 million as of June 30, 2020, including $230.0 million from its IPO.
Completed a $230 million initial public offering (IPO).
Appointed Matthew Norkunas, M.D., MBA as Chief Financial Officer.
Cash, cash equivalents and marketable securities were $301.1 million as of June 30, 2020.
Net loss was $17.7 million for the quarter ended June 30, 2020.
Generation Bio
Generation Bio
Forward Guidance
The press release contains forward-looking statements regarding the company's future expectations, plans, and prospects, which are subject to various risks and uncertainties.